Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again
by Gene Marcial on Feb.14, 2011, under Towing
From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculation that a Big Pharma will buy Clinical Data.
Continue reading Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again
Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again originally appeared on DailyFinance on Mon, 14 Feb 2011 08:00:00.
Filed Under: Company News, Columns, Investing, Health Care, Pfizer, Stock Picks, Merck, GlaxoSmithKline, Eli Lilly
-
You Can Reach Us At:
For All Of Your Towing and Recovery Needs.
Tele: (847) 587-6076
Fax: (847) 587-8610 Some Of Our Pics
